lincTreg1-Targeting Oligonucleotides for Specific Treg Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies lack effective strategies to modulate the expression of the lincTreg1 gene, which is crucial for regulating regulatory T cell function and immune homeostasis, leading to unbalanced immune responses in conditions like autoimmunity and cancer.
Innovation Solution
Development of oligonucleotides that specifically target and bind to the lincTreg1 gene or its RNA transcript, either silencing or activating its expression through antisense techniques, RNA interference, or CRISPR-Cas systems, to modulate Treg cell function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If oligonucleotides are designed to target lincTreg1 gene, then specific binding to lincTreg1 is achieved, but off-target binding to similar sequences may occur
Solution Approach 1:
The patent applies local quality by designing oligonucleotides with differentiated binding characteristics - using higher GC content regions for stronger specific binding while avoiding regions with potential off-target homology. The oligonucleotide sequences are optimized to have specific local compositional features that enhance target specificity while minimizing off-target effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying oligonucleotide sequence parameters (nucleotide composition, GC content, length) to optimize binding specificity. Multiple oligonucleotide variants are designed with different sequence parameters to identify those with maximum specificity for lincTreg1 while minimizing off-target binding.
2Reliability
If oligonucleotide sequences are optimized for high binding affinity, then effective gene modulation is achieved, but increased immunogenicity may result
Solution Approach 1:
The patent applies parameter changes by optimizing oligonucleotide physical-chemical parameters including GC content (maintained within 40-60% range), length (18-25 nucleotides), and sequence composition to balance binding affinity with reduced immunogenicity. Chemical modifications are also applied to alter physical parameters while maintaining binding effectiveness.
Solution Approach 2:
The patent uses chemical modifications as intermediary structures that mediate between the need for high binding affinity and reduced immunogenicity. Modifications such as phosphorothioate backbones, 2'-O-methyl ribose, and locked nucleic acid (LNA) residues act as intermediaries that enhance stability and binding while reducing immune system recognition.
3Measurement precision
If comprehensive screening of test compounds is performed, then accurate identification of candidate compounds is achieved, but increased time and resource consumption occurs
Solution Approach 1:
The patent applies segmentation by dividing the compound screening process into distinct modular assays - initial high-throughput filtering assays followed by more detailed functional validation assays. This segmented approach allows rapid identification of promising candidates followed by thorough characterization, reducing overall screening time while maintaining accuracy.
Solution Approach 2:
The patent employs partial action by implementing a tiered screening strategy where not all compounds undergo the complete validation process. Initial screens use simplified assays to identify a subset of promising compounds that then receive full validation, achieving accurate identification with reduced time and resource investment compared to comprehensive screening of all compounds.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oligonucleotides effectively modulate Treg cell activity, providing therapeutic benefits in autoimmunity and cancer by enhancing or suppressing immune responses as needed.
Implementation Method 1
oligonucleotide which targets human lincTreg1 gene and specifically binds to a nucleic acid sequence thereof
Data Source
AI summary
The invention relates to a previously uncharacterized gene lincTreg1 and to its long non-coding RNA transcripts as molecular targets for developing novel strategies to combat diseases that involve unbalanced immune system. In particular, the invention relates to oligonucleotides capable of modulating the expression of lincTreg1 for use in treating diseases for which modulating immune response is desirable.